A Brief Overview of I AM ALS [Video]

I AM ALS responds to FDA Advisory Committee vote against NurOwn for the treatment of ALS

I AM ALS - an organization led for and by those living with and impacted by amyotrophic lateral sclerosis (ALS) - objects to today’s Cellular, Tissue, and Gene Therapies Advisory Committee (AdComm) vote of 17 to 1, with one member abstaining, to not recommend NurOwn be approved by the FDA for the treatment of ALS.

I AM ALS letter to FDA asking for consistency in Advisory Committee evaluation of ALS treatments

I AM ALS and members of the ALS community are disappointed that the question being posed to the Advisory Committee fails to adhere to the same pattern of flexibility recognizing the significant unmet medical need of ALS as was the case for previous Advisory Committee meetings for ALS treatments.

September 26 – Update to I AM ALS statement regarding NurOwn Advisory Committee Meeting